- Home
- LU vs ZLAB Comparison
LU vs ZLAB Comparison
Compare LU & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LU | ZLAB |
|---|---|---|
| Founded | 2005 | 2013 |
| Country | China | China |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.0B |
| IPO Year | 2020 | 2017 |
Fundamental Metrics
Financial Performance| Metric | LU | ZLAB |
|---|---|---|
| Price | $2.69 | $17.10 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $53.52 |
| AVG Volume (30 Days) | ★ 1.1M | 750.8K |
| Earning Date | 03-23-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,671,260,668.00 | $441,629,000.00 |
| Revenue This Year | N/A | $26.16 |
| Revenue Next Year | $1.62 | $30.62 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 24.14 |
| 52 Week Low | $2.25 | $16.82 |
| 52 Week High | $4.57 | $44.34 |
Technical Indicators
Market Signals| Indicator | LU | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 52.51 | 36.19 |
| Support Level | $2.63 | $18.40 |
| Resistance Level | $2.75 | $19.14 |
| Average True Range (ATR) | 0.09 | 0.60 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 63.41 | 3.37 |
Price Performance
Historical ComparisonAbout LU Lufax Holding Ltd each representing two (2)
Lufax Holding Ltd is a technology-empowered personal financial services platform in China. The company address the large unmet demand for personal lending among small business owners as well as salaried workers in China and provides tailor-made wealth management solutions to China's middle class and affluent population. Its platform has two hubs namely Retail Credit Facilitation Hub and Wealth Management Hub.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.